MedTrace Logo

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

NCT06443684 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 305

Last updated 2025-01-07

No results posted yet for this study

Summary

The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment. The main question it aims to answer is:

1\) Whether MRD(Minimal residual disease) status can predict recurrence events in stage III driven-mutant NSCLC in advance

Conditions

  • Non Small Cell Lung Cancer

Interventions

DIAGNOSTIC_TEST

MRD

MRD（LC-10）include 10 lung cancer-related driver gene mutation site

Sponsors & Collaborators

  • Shanghai Chest Hospital

    lead OTHER

Principal Investigators

  • Shun Lu, M.D. · Shanghai Chest Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-08
Primary Completion
2025-03-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06443684 on ClinicalTrials.gov